Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development - - Stephen From Elevated from Chief Executive Officer to Executive Chairman - WALTHAM, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Franz Obermayr, Ph.D., Man...
WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that it has entered into a securities purchase agreement in connection with a private placement (the “Private Placement”) with an affiliate of Armistice Capital, LLC (“Armistice”) for aggregate gross pro...
By Beth Senko, CFA NASDAQ:EYEG READ THE EYEG RESEARCH REPORT HERE EyeGate Pharmaceuticals is a late-stage clinical company developing better solutions to current treatments for post-surgical eye care and moderate to severe dry eye using OBG, its proprietary cross- linked formulation of sodium hyaluronate (HA). On December 18, 2020, EyeGate Pharmaceuticals (NASDAQ:EYEG) announced it will acquire
M&A momentum in the biopharma space picked up pace, with a few more deals announced in the space this week.Agios To Divest Oncology Portfolio: In a streamlining bid and to have a singular focus Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced it's divesting its commercial and clinical-stage oncology portfolio to French biotech Servier for $2 billion.Of the total proceeds, $1.8 billion will be received as upfront cash payment and $200 million in potential future milestone payment for voraside...
Today's 5 Stock Ideas: * Eyegate Pharmaceuticals (EYEG) \- The company announced the acquisition of Panoptes Pharma. The acquisition added to EyeGate's pipeline. Shares traded roughly 80% higher premarket today. * Nike (NKE) \- The company announced better-than-expected Q2 EPS and sales results and an increase in digital sales on Friday after the close. Shares traded roughly 4% higher premarket today. * Zoom Video (ZM) \- Shares traded roughly 4% higher premarket. This could be due to increa...
Expands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Target Side EffectsAcquisition Strengthens Leadership Team with Appointment of Panoptes Co-Founders Dr. Franz Obermayr as EVP Clinical Development and Dr. Stefan Sperl as EVP CMC and OperationsWALTHAM, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc....
By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT EyeGate Pharmaceuticals (NASDAQ:EYEG) is a late-stage clinical company developing better solutions to current treatments for post-surgical eye care and moderate to severe dry eye using OBG, its proprietary cross- linked formulation of sodium hyaluronate (HA). The Company is preparing its IND filing for OBG as an alternative to a
WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc.